TORONTO, Aug 1, 2024
/CNW/ - Linepharma International Inc., a subsidiary of Nordic
Group B.V. (NORDIC PHARMA), is pleased to announce that
PrNORDIMET (methotrexate), the first methotrexate
single-use prefilled pen for self-injection, is now available in
Canada for the treatment of adult
patients with 1:
- Severe disabling active rheumatoid arthritis (RA)
1
- Severe disabling psoriasis/psoriatic arthritis, specifically
for cases that are recalcitrant and have not responded adequately
to other therapies, following a dermatologic consultation.
1
"We are excited to introduce NORDIMET to the Canadian market,"
said Dana Tenenbaum, General Manager
at NORDIC PHARMA. "We believe it will be a valuable addition to the
therapeutic options available for managing severe RA and
psoriasis."
RA remains the leading cause of pain and disability in
North
America.2 Patients with RA often experience
unpredictable outcomes and a gradual decline in quality of life
despite current treatments.3 RA affected an estimated
1.24% of the Canadian population in 2021.4
Methotrexate, a Disease-Modifying Antirheumatic Drug (DMARD), is
considered a cornerstone therapy for rheumatoid arthritis and
psoriasis. It has well-established safety and efficacy profiles, is
recognized internationally and locally in treatment guidelines, and
has proven effective both as a monotherapy and in combination with
other therapies.5
In recent years, significant advancements have occurred in the
understanding and managing of RA. Methotrexate has been used
since the 1980s and continues to be the anchor drug in RA treatment
today. It is recognized for its effectiveness both as a standalone
therapy and in combination with glucocorticoids, other conventional
synthetic DMARDs, biological DMARDs, and targeted synthetic
DMARDs.5 With methotrexate, the subcutaneous route of
administration has been acknowledged as the most effective option
and offers a favorable risk-benefit ratio compared to the oral
route.5
For over a decade, Nordic Group B.V. has been building its
therapeutic Rheumatology portfolio in Europe through close collaboration with
patients and physicians.6 The approval of
PrNORDIMET by Health Canada on March 26th, 2024, and its launch in
the Canadian market marks the continued commitment of the Nordic
Group B.V. to address unmet medical needs through expanding its
innovative solutions for patients' treatments to new markets
outside Europe.
PrNORIDMET is distributed in Canada by Linepharma International Inc.
(NORDIC PHARMA), a subsidiary of Nordic Group B.V.
For more information about PrNORDIMET and its
availability, please contact NORDIC PHARMA through
nordicpharma.ca.
About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-sized
international pharmaceutical company that focuses on the
development and commercialization of specialty products.
Portfolio enhancement has been accomplished through targeted
developments and focused acquisitions to build a foundation in
Eye Care, Rheumatology and Women's Health. Nordic Group has
established deep roots throughout Europe and, more recently, expanded
outside of Europe with
increased acquisitions worldwide.5
Nordic Group is part of SEVER Life Sciences, a holding company
created in 2019 that brings together three diverse but
complementary companies offering a wide range of products,
pharmaceutical development services, and delivery technologies.
1- Product Monograph of
Nordimet
|
2- Canadian Chronic
Disease Surveillance System (CCDSS) data, August 2019.
|
3- Cross M et al. The
global burden of rheumatoid arthritis: estimates from the Global
Burden of Disease 2010 Study. Ann Rheum Dis. 2014;
73:1316-22.
|
4- Canadian Chronic
Disease Surveillance System (CCDSS) data files, as of September
2023_
https://health-infobase.canada.ca/ccdss/data-tool/?G=00&V=27&M=2
|
5- Smolen JS, Landewé
RBM, Bijlsma JWJ, et al. Ann Rheum Dis 2020; 79:685–699.
|
6-
www.nordicpharma.com
|
SOURCE NORDIC PHARMA